Navigation Links
CNS Response Announces Fiscal Third Quarter 2007 Results
Date:8/19/2007

Net loss for the three-month period ended June 30, 2007 was $(502,700), or $(0.02) per diluted share, compared to a net loss of $(510,000), or $(0.25) per diluted share, during the same period last year. The net loss for the three month period ended June 30, 2007 consists of an operating loss of $(557,900) offset by other income of $55,200. The net loss for the three month period ended June 30, 2006 consists of an operating loss of $(363,900) and interest expense of $(146,100). The increase in operating loss is due primarily to the costs incurred in connection with the ongoing multi-site clinical study.

About CNS Response

CNS Response is a life sciences company focused on the commercialization of the first patented system that guides psychiatrists in pharmacotherapy for patients with certain behavioral disorders. The Company's system, "Referenced-EEG(SM)" or "rEEG(SM)", is the first objective, physiology-based system consistently shown to guide psychiatrists to appropriate treatment in the most challenging patients. It is the culmination of a 20-year effort combining Quantitative Medicine, Psychiatry and Pathology that allows a physician for the first time to determine objectively which CNS (central nervous systems) medications will be effective for a particular patient..

rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, C
'/>"/>

SOURCE CNS Response, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Speaker announces business members of IT Task Force
6. Doyle announces technology tax credits for Berbee
7. Doyle announces new energy, global warming policies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4
Other Biology Technology:measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 2measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 3measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 4measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 5measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 6measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 7measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 8measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 9measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 10measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 11measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 12measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 13measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 14measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 15Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 2Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 3Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 4Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 5Protocol for GenomePlex Whole Genome Amplification from Plant 2Protocol for GenomePlex Whole Genome Amplification from Plant 3Protocol for GenomePlex Whole Genome Amplification from Plant 4Protocol for GenomePlex Whole Genome Amplification from Plant 5Protocol for GenomePlex Whole Genome Amplification from Plant 6
Breaking Biology News(10 mins):Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Successful stem cell therapy for treatment of eye disease 2Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 1Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 1Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 2Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 4Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 5Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 6Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 7Regences Social Media Web Site Gets a Facelift 60731 1Regences Social Media Web Site Gets a Facelift 60731 2